MED30

Across TCGA pan-cancer cohorts, MED30 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MED30 data layer compared with 24 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MED30 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MED30 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where MED30 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.264	0.523	<.001	44	view →
LSCC	OS	Median	II,III,IV	0.923	0.542	<.001	37	view →
HNSC	DFS	Tertile	III,IV	0.616	0.848	.031	31	view →
CCRCC	OS	Median	II,III,IV	0.454	1.000	.014	6	view →
LUAD	DFS	Tertile	II,III,IV	0.943	0.757	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MED30–PDAC (DFS)

Open the PDAC breakdown →